Language selection

Government of Canada / Gouvernement du Canada

Search

Literature review update on the efficacy and effectiveness of high-dose (Fluzone® High-Dose) and MF59-adjuvanted (Fluad®) trivalent inactivated influenza vaccines in adults 65 years of age and older .: HP40-210/2018E-PDF

“Two trivalent inactivated influenza vaccines (TIVs) designed specifically for adults 65 years of age and older are currently authorized for use in Canada: a high-dose vaccine (Fluzone® High-Dose, Sanofi Pasteur) and an MF59-adjuvanted vaccine (Fluad®, Seqirus). Previous literature reviews on the efficacy and effectiveness, immunogenicity and safety of Fluzone® High-Dose and Fluad® have been conducted to inform NACI’s recommendations on the use of these vaccines in the annual NACI Advisory Committee Statement: Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine. To ensure that these recommendations continue to be informed with the most current literature, the present literature review was conducted to identify additional efficacy and effectiveness evidence published since the original literature reviews”--Executive summary, p. 4.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.852907&sl=0

Publication information
Department/Agency
  • Canada. National Advisory Committee on Immunization.
  • Public Health Agency of Canada.
TitleLiterature review update on the efficacy and effectiveness of high-dose (Fluzone® High-Dose) and MF59-adjuvanted (Fluad®) trivalent inactivated influenza vaccines in adults 65 years of age and older .
Variant title
  • Efficacy and effectiveness of high-dose and MF59-adjuvanted trivalent inactivated influenza vaccines in adults 65 years of age and older
  • At head of title: Advisory committee review, National Advisory Committee on Immunization (NACI)
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Issued also in French under title: Mise à jour sur la revue de la littérature portant sur l’efficacité potentielle et réelle des vaccins antigrippaux trivalents inactivés à forte dose (FluzoneMD Haute dose) et contenant l’adjuvant MF59 (FluadMD) chez les adultes âgés de 65 ans et plus.
  • Cover title.
  • "Publication date: May 2018."
  • Prepared by: L. Zhao ... [et al.]. Cf. Acknowledgements.
  • Includes bibliographical references (p. 17-19).
Publishing information
  • [Ottawa] : Public Health Agency of Canada, 2018.
Description39 p.
ISBN9780660255545
Catalogue number
  • HP40-210/2018E-PDF
Departmental catalogue number170493
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details

Report a problem or mistake on this page
Date modified: